Format

Send to

Choose Destination
Br J Cancer. 2017 Sep 5;117(6):856-866. doi: 10.1038/bjc.2017.244. Epub 2017 Jul 27.

Prognostic biomarkers for oral tongue squamous cell carcinoma: a systematic review and meta-analysis.

Author information

1
Department of Pathology, University of Helsinki, Helsinki, Finland.
2
Department of Oral and Maxillofacial Diseases, University of Helsinki, Helsinki, Finland.
3
Institute of Dentistry, University of Misurata, Misurata, Libya.
4
Department of Otorhinolaryngology- Head and Neck Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
5
Department of Oral Diagnosis, School of Dentistry, State University of Campinas, Piracicaba, São Paulo, Brazil.
6
Department of Mathematical Sciences and Statistics, University of Oulu, Oulu, Finland.
7
Department of Pathology, University of Turku, Turku, Finland.
8
Department of Pathology, HUSLAB, Helsinki University Hospital, Helsinki, Finland.
9
Department of Diagnostics and Oral Medicine, Research Group of Cancer Research and Translational Medicine, Medical Faculty, University of Oulu, Oulu, Finland.
10
Medical Research Center, Oulu University Hospital, Oulu, Finland.

Abstract

BACKGROUND:

Identifying informative prognostic biomarkers for oral tongue squamous cell carcinoma (OTSCC) is of great importance in order to better predict tumour behaviour and to guide treatment planning. Here, we summarise existing evidence regarding immunohistochemical prognostic biomarkers for OTSCC.

METHODS:

A systematic search of the literature was performed using the databases of Scopus, Ovid Medline, Web of Science and Cochrane Library. All studies which had investigated the prognostic significance of immunohistochemical biomarkers in OTSCC during the period from 1985 to 2015 were retrieved. For the five most often evaluated biomarkers a random-effects meta-analysis on overall survival was performed, including those studies that provided the necessary statistical results.

RESULTS:

A total of 174 studies conducted during the last three decades were found, and in these 184 biomarkers were evaluated for the prognostication of OTSCC. The five biomarkers most frequently assessed were p53, Ki-67, p16, VEGFs and cyclin D1. In the meta-analyses, the most promising results of the prognostic power for OTSCC were obtained for cyclin D1. For studies of VEGF A and C the results were equivocal, but the pooled analysis of VEGF A separately showed it to be a useful prognosticator for OTSCC. There was no sufficient evidence to support p53, Ki-67 and p16 as prognostic biomarkers for OTSCC. Limitations in the quality of the published studies (e.g., small cohorts, lack of compliance with REMARK guidelines) are widespread.

CONCLUSIONS:

Numerous biomarkers have been presented as useful prognosticators for OTSCC, but the quality of the conduct and reporting of original studies is overall unsatisfactory which does not allow reliable conclusions. The value of two biomarkers (VEGF-A and cyclin D1) should be validated in a multicentre study setting following REMARK guidelines.

PMID:
28751758
PMCID:
PMC5589992
DOI:
10.1038/bjc.2017.244
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center